Effect of AK4 on Proliferation and Migration of Intrahepatic Bile Duct Carcinoma Cell HUCCT1

Zhoujun LIAO; Shaohua YANG; Lixin LIU; Sheng HU; Yihui CHEN; Qiang KANG; Xiaowen ZHANG

doi:10.12259/j.issn.2095-610X.S20220611

Volume 43 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2022 > 43(6): 1-6

Yixun LI, Kun WU, Rui CHEN, Liying WANG, Zhuoma SINAN, Chunyan XIA. Evaluation of Red Blood Cell Fragment Parameter Detection of Automatic Hematology Analyzer[J]. Journal of Kunming Medical University, 2022, 43(4): 93-98. doi: 10.12259/j.issn.2095-610X.S20220415

Citation:

Zhoujun LIAO, Shaohua YANG, Lixin LIU, Sheng HU, Yihui CHEN, Qiang KANG, Xiaowen ZHANG. Effect of AK4 on Proliferation and Migration of Intrahepatic Bile Duct Carcinoma Cell HUCCT1[J]. Journal of Kunming Medical University, 2022, 43(6): 1-6. doi: 10.12259/j.issn.2095-610X.S20220611

Citation:

PDF( 2099 KB)

Effect of AK4 on Proliferation and Migration of Intrahepatic Bile Duct Carcinoma Cell HUCCT1

doi: 10.12259/j.issn.2095-610X.S20220611

Dept. of Hepatobiliary Surgery，The 2nd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2022-03-26
Available Online: 2022-06-07
Publish Date: 2022-06-30

Abstract

Abstract

Objective To investigate the effects of AK4 on the proliferation and migration of intrahepatic bile duct carcinoma cells HUCCT1. Methods Small interfering RNA （siRNA） technology was used to target the silencing of AK4 expression in HUCCT1 of intrahepatic bile duct cancer cells. Western blot was used to detect the transfection efficiency of siRNA and screen siRNA-AK4. The proliferation and migration ability of the bile duct cancer cells were detected by EdU assay and cell scar assay. Results EdU experiment showed that cell proliferation decreased after AK4 silencing （P < 0.05）, the cell migration ability was decreased after AK4 silencing （P < 0.01）. Conclusion AK4 can enhance the proliferation and migration of HUCCT1 in intrahepatic bile duct carcinoma cells.
- Intrahepatic cholangiocarcinoma,
- AK4,
- Proliferation,
- Migration

FullText(HTML)

References(26)

References

[1]	El-diwany R,Pawlik T M,Ejaz A. Intrahepatic Cholangiocarcinoma[J]. Surgical oncology clinics of North America,2019,28(4):587-599. doi: 10.1016/j.soc.2019.06.002
[2]	Kelley R K,Bridgewater J,Gores G J,et al. Systemic therapies for intrahepatic cholangiocarcinoma[J]. J Hepatol,2020,72(2):353-363. doi: 10.1016/j.jhep.2019.10.009
[3]	Yoneda T,Sato M,Maeda M,et al. Identification of a novel adenylate kinase system in the brain:cloning of the fourth adenylate kinase[J]. Brain research Molecular brain research,1998,62(2):187-195. doi: 10.1016/S0169-328X(98)00249-6
[4]	Yamamoto T,Kikkawa R,Yamada H,et al. Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver:toxicity differentiation in hepatotoxicants[J]. The Journal of toxicological sciences,2006,31(1):49-60. doi: 10.2131/jts.31.49
[5]	Dzeja P,Terzic A. Adenylate kinase and AMP signaling networks:metabolic monitoring,signal communication and body energy sensing[J]. International journal of molecular sciences,2009,10(4):1729-1772. doi: 10.3390/ijms10041729
[6]	Choi S B,Kim K S,Choi J Y,et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection:association of lymph node metastasis and lymph node dissection with survival[J]. Annals of surgical oncology,2009,16(11):3048-3056. doi: 10.1245/s10434-009-0631-1
[7]	Endo I,Gonen M,Yopp A C,et al. Intrahepatic cholangiocarcinoma:rising frequency,improved survival,and determinants of outcome after resection[J]. Annals of surgery,2008,248(1):84-96. doi: 10.1097/SLA.0b013e318176c4d3
[8]	Gray S, Lamarca A, Edeline J, et al. Targeted Therapies for Perihilar Cholangiocarcinoma [J]. Cancers, 2022, 14（7）.
[9]	Wirth T C,Vogel A. Surveillance in cholangiocellular carcinoma[J]. Best practice & research Clinical gastroenterology,2016,30(6):987-99.
[10]	Weigt J,Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. Expert review of gastroenterology & hepatology,2010,4(4):395-397.
[11]	Kato A,Shimizu H,Ohtsuka M,et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer:a retrospective single-center study[J]. Annals of surgical oncology,2013,20(1):318-324. doi: 10.1245/s10434-012-2312-8
[12]	Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery [J]. Annals of surgical oncology, 2015, 22 Suppl 3: S1093-9109.
[13]	Malka D,Cervera P,Foulon S,et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO):A randomised,open-label,non-comparative phase 2 trial[J]. The Lancet Oncology,2014,15(8):819-828. doi: 10.1016/S1470-2045(14)70212-8
[14]	Lee J,Park S H,Chang H M,et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer:a multicentre,open-label,randomised,phase 3 study[J]. The Lancet Oncology,2012,13(2):181-188. doi: 10.1016/S1470-2045(11)70301-1
[15]	Primrose J N,Fox R P,Palmer D H,et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP):a randomised,controlled,multicentre,phase 3 study[J]. The Lancet Oncology,2019,20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X
[16]	Zhu A X,Macarulla T,Javle M M,et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation:The Phase 3 Randomized Clinical ClarIDHy Trial[J]. JAMA oncology,2021,7(11):1669-677. doi: 10.1001/jamaoncol.2021.3836
[17]	Abou-alfa G K,Macarulla T,Javle M M,et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy):a multicentre,randomised,double-blind,placebo-controlled,phase 3 study[J]. The Lancet Oncology,2020,21(6):796-807.
[18]	Demols A,Borbath I,Van Den Eynde M,et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN,a randomized,double-blind,phase II trial[J]. Annals of oncology:official journal of the European Society for Medical Oncology,2020,31(9):1169-1177.
[19]	Sirica A E,Gores G J,Groopman J D,et al. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances[J]. Hepatology,2019,69(4):1803-1815.
[20]	Kalckar H M. Spectroscopic microdetermination of muscle adenylic acid[J]. Science,1944,99(2563):131-132.
[21]	Amiri M,Conserva F,Panayiotou C,et al. The human adenylate kinase 9 is a nucleoside mono- and diphosphate kinase[J]. The international journal of biochemistry & cell biology,2013,45(5):925-931.
[22]	Miyoshi K,Akazawa Y,Horiguchi T,et al. Localization of adenylate kinase 4 in mouse tissues[J]. Acta histochemica et cytochemica,2009,42(2):55-64.
[23]	田华,何小勇,王道猛,等. 腺苷酸激酶4在肺腺癌中的表达及其临床意义[J]. 中国癌症杂志,2021,31(2):108-113.
[24]	李辰运,孙彤,卓娜,等. 胰腺导管腺癌中腺苷酸激酶4的表达及临床意义[J]. 天津医科大学学报,2018,24(1):43-46.
[25]	李绍军,雷益,易文全,等. 食管鳞状细胞癌组织miR-199a-3p、AK4表达水平及临床意义[J]. 遵义医科大学学报,2021,44(6):756-761.
[26]	夏林,王劲松. 胃癌组织中腺苷酸激酶4和HIF-1α的表达及其临床意义[J]. 临床与实验病理学杂志,2021,37(4):452-454+457.

Relative Articles(20)

Relative Articles

[1]	Yiran YAN, Chengwan SHEN, Xiangyu SHANG, Chan FENG, Jinqiu LI, Hasim AXIANGU. Galangin Inhibits the Migration and Invasion of Cervical Cancer Hela Cells Through Hippo/YAP Pathway. Journal of Kunming Medical University, 2025, 46(1): 36-42. doi: 10.12259/j.issn.2095-610X.S20250105
[2]	Yuru ZHAI, Yan BAI, Yunyun LI. FGF2 Regulates Hypoxia-Induced Proliferation and Collagen Metabolism of Scleral Fibroblasts Through the PERK/EIF2α/ATF4 Signaling Pathway. Journal of Kunming Medical University, 2024, 45(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20241004
[3]	Xiangchuan QIN, Jinqiu LI, Xiaojing HUANG, Kuerban HUTUBIDING·, Hasim AXIANGU·. Effect of HPV E6 on Proliferation，Invasion and Migration of Cervical Cancer Cells Through Rap1 Signaling Pathway. Journal of Kunming Medical University, 2024, 45(9): 9-16. doi: 10.12259/j.issn.2095-610X.S20240902
[4]	Ming ZHANG, Chenglong YU, Jinpeng CAO. ZNF384 Regulates Metastasis of Hepatocellular Carcinoma via GCLM. Journal of Kunming Medical University, 2023, 44(11): 56-62. doi: 10.12259/j.issn.2095-610X.S20231108
[5]	Liang ZHANG, Baoquan WANG, Xifeng LEI, Xu WANG, Yang KE, Wei ZHANG. Effect of miR-29c-3p/IGF1 Molecular Axis on Activation，Proliferation and Apoptosis of Hepatic Stellate Cells. Journal of Kunming Medical University, 2023, 44(9): 7-14. doi: 10.12259/j.issn.2095-610X.S20230926
[6]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[7]	Li ZHANG, Qingcen WANG, Luohui ZHOU, Juan YANG, Hong WANG. Luteolin Inhibits HASMCs Migration by Endoplasmic Reticulum Stress. Journal of Kunming Medical University, 2022, 43(5): 12-17. doi: 10.12259/j.issn.2095-610X.S20220518
[8]	Gang LI, Shaohua YANG, Meng SHEN, Nan XIE, Guanbo ZHANG, Jiaxing WANG, Jinsong LI. Expression and Clinical Significance of Eukaryotic Translation Initiation Factors 5A2 and Ki67 in Intrahepatic Cholangiocarcinoma. Journal of Kunming Medical University, 2022, 43(6): 7-12. doi: 10.12259/j.issn.2095-610X.S20220630
[9]	Bin ZHAO, Yuanpeng DUAN, Guoying ZHANG, Chengwei BI, Libo YANG, Zhiyu SHI, Yong YANG, Jianpeng ZHANG, Ting GAO. CircRNA EZH2 Promotes Proliferation and Migration of Prostate Cancer Cells by Regulating miR-30c-5p. Journal of Kunming Medical University, 2022, 43(7): 25-32. doi: 10.12259/j.issn.2095-610X.S20220731
[10]	Shao-hua YANG, Zhou-Jun LIAO, Sheng HU, Mao-lin HONG, Zhi-Mei SONG, Qun WEI, Xiao-wen ZHANG. The Expression and Significance of Eukaryotic Translation Initiation Factor-5A2 in Intrahepatic Cholangiocarcinoma. Journal of Kunming Medical University, 2021, 42(5): 24-28. doi: 10.12259/j.issn.2095-610X.S20210505
[11]	Lan YANG, Xiao JIA, Yi-tong JIANG, Qi CUI, Guang-ci LIU, Ying-hong HE. The Effect of Silencing of UBE2C Gene on the Proliferation and Migration of Human Gastric Cancer AGS Cells. Journal of Kunming Medical University, 2021, 42(5): 18-23. doi: 10.12259/j.issn.2095-610X.S20210504
[12]	Gang LI, Jin-song LI, Nan XIE, Chun-mang LI, Lei WEI, Fan CAO, Ying-zhen SU. Expression of B7-H4 in Intrahepatic Cholangiocarcinoma and Its Clinical Significance. Journal of Kunming Medical University, 2021, 42(4): 78-83. doi: 10.12259/j.issn.2095-610X.S20210415
[13]	Li Shan Shan , Quan Yu Hang , Gong Ling Li , Yang Hui , Pu Jing Hong , Wang Zhong Hui . . Journal of Kunming Medical University, 2020, 41(05): 103-107.
[14]	Pang Yue Wen , Gong Hui Jie , Wang Ling , Shi Jing , Duan JunYao , Feng Ying Ying , Yan Yong Ji . . Journal of Kunming Medical University, 2019, 40(08): 22-27.
[15]	Wei Dong . Effect of Fragile Site WWOX Gene on Regulating Proliferation of Human Gallbladder Cancer Cells in Vitro. Journal of Kunming Medical University,
[16]	Li Zheng . The Diagnosis of Intrahepatic Bile Duct Stones with Early Intrahepatic Cholangiocarcinoma by Combining CA199, CEA, CA50 and ALP and Magnetic Resonance Imaging. Journal of Kunming Medical University,
[17]	Liu Li Xin . . Journal of Kunming Medical University,
[18]	Shi Zhao Kun . . Journal of Kunming Medical University,
[19]	Wang Hai Feng . . Journal of Kunming Medical University,
[20]	Liu Jia Xin . . Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	吴玉. 血栓相关指标检测对急性心肌梗死患者发生主要不良心血管事件的预测价值. 中国当代医药. 2023(02): 163-166+170 .
2.	余东. 红细胞参数和转铁蛋白含量在贫血鉴别诊断中的价值. 临床研究. 2023(05): 140-143 .
3.	陈辉，宋开源，彭灿辉. 红细胞碎片计数与红细胞碎片比例对脓毒症患者预后评估的应用研究. 中华预防医学杂志. 2023(08): 1246-1252 .
4.	李智杰. Sysmex XN-3000血液分析仪检测外周血有核红细胞的临床价值. 中国医疗器械信息. 2022(22): 40-42 .